Umbralisib

Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds TG Therapeutics, Inc. (TGTX) Investors of Class Action and Last Few Hours to Actively Participate

Retrieved on: 
Friday, September 16, 2022

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in TG Therapeutics, you have until September 16, 2022, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

TG Therapeutics, Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit; September 16, 2022 Deadline; Portnoy Law Firm

Retrieved on: 
Thursday, September 15, 2022

LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) investors that a class action filed on behalf of investors. TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.        

Key Points: 
  • LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX) investors that a class action filed on behalf of investors.
  • TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Thursday, September 15, 2022

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

TG THERAPEUTICS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, September 15, 2022

Investors have until September 16, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 16, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • On this news, TG Therapeutics stock price fell $8.16 per share, or 34.93%, to close at $15.20 per share on November 30, 2021.
  • On this news, TG Therapeutics stock price fell $1.93 per share, or 21.81%, to close at $6.92 per share on April 18, 2022.

TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)

Retrieved on: 
Tuesday, September 13, 2022

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • If you purchased TG Therapeutics securities, and/or would like to discuss your legal rights and options please visit TG Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

TGTX 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm’s Attorneys Before Sept. 16th Deadline in Securities Fraud Class Action

Retrieved on: 
Monday, September 12, 2022

Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.

Key Points: 
  • Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.
  • Finally, on June 1, 2022 the FDA announced that it revoked approval for Umbralisib for treating MZL and FL due to safety concerns.
  • Were focused on investors losses and whether TG misrepresented safety data in connection with its submissions to the FDA, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in TG Therapeutics and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

TGTX DEADLINE ALERT: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important September 16 Deadline in Securities Class Action – TGTX

Retrieved on: 
Saturday, September 10, 2022

WHAT TO DO NEXT: To join the TG Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=7662 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the TG Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=7662 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than September 16, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

TG Therapeutics, Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit; September 16, 2022 Deadline; Portnoy Law Firm

Retrieved on: 
Wednesday, September 7, 2022

LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) investors that a class action filed on behalf of investors. TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX) investors that a class action filed on behalf of investors.
  • TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

TG THERAPEUTICS, INC. (NASDAQ: TGTX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TG Therapeutics, Inc. (NASDAQ: TGTX)

Retrieved on: 
Tuesday, September 6, 2022

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • If you purchased TG Therapeutics securities, and/or would like to discuss your legal rights and options please visit TG Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

TGTX 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm’s Attorneys Before Sept. 16th Deadline in Securities Fraud Class Action

Retrieved on: 
Tuesday, September 6, 2022

Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.

Key Points: 
  • Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data.
  • Finally, on June 1, 2022 the FDA announced that it revoked approval for Umbralisib for treating MZL and FL due to safety concerns.
  • Were focused on investors losses and whether TG misrepresented safety data in connection with its submissions to the FDA, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in TG Therapeutics and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .